GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (NAS:NVAX) » Definitions » Shiller PE Ratio

Novavax (Novavax) Shiller PE Ratio : (As of Apr. 30, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Novavax Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Novavax Shiller PE Ratio Historical Data

The historical data trend for Novavax's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Shiller PE Ratio Chart

Novavax Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Novavax Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Novavax's Shiller PE Ratio

For the Biotechnology subindustry, Novavax's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novavax's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Novavax's Shiller PE Ratio falls into.



Novavax Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Novavax's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Novavax's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.47/129.4194*129.4194
=-1.470

Current CPI (Dec. 2023) = 129.4194.

Novavax Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -1.400 99.695 -1.817
201406 -1.600 100.560 -2.059
201409 -1.600 100.428 -2.062
201412 -2.600 99.070 -3.397
201503 -2.000 99.621 -2.598
201506 -1.600 100.684 -2.057
201509 -2.400 100.392 -3.094
201512 -5.800 99.792 -7.522
201603 -5.800 100.470 -7.471
201606 -5.800 101.688 -7.382
201609 -4.800 101.861 -6.099
201612 -4.200 101.863 -5.336
201703 -3.200 102.862 -4.026
201706 -3.200 103.349 -4.007
201709 -3.010 104.136 -3.741
201712 -3.200 104.011 -3.982
201803 -2.800 105.290 -3.442
201806 -2.370 106.317 -2.885
201809 -2.330 106.507 -2.831
201812 -2.600 105.998 -3.175
201903 -2.110 107.251 -2.546
201906 -1.690 108.070 -2.024
201909 -0.740 108.329 -0.884
201912 -1.130 108.420 -1.349
202003 -0.580 108.902 -0.689
202006 -0.300 108.767 -0.357
202009 -3.210 109.815 -3.783
202012 -2.700 109.897 -3.180
202103 -3.050 111.754 -3.532
202106 -4.750 114.631 -5.363
202109 -4.310 115.734 -4.820
202112 -11.180 117.630 -12.301
202203 2.560 121.301 2.731
202206 -6.530 125.017 -6.760
202209 -2.150 125.227 -2.222
202212 -2.280 125.222 -2.356
202303 -3.410 127.348 -3.465
202306 0.580 128.729 0.583
202309 -1.260 129.860 -1.256
202312 -1.470 129.419 -1.470

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novavax  (NAS:NVAX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Novavax Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Novavax's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novavax (Novavax) Business Description

Traded in Other Exchanges
Address
21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.
Executives
Filip Dubovsky officer: President, R&D C/O NOVAVAX INC., 21 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Gregory M Glenn officer: President, R&D 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
Elaine O'hara officer: EVP, Chief Strategy Officer 333 NORTH WARREN AVENUE, MALVERN PA 19355
John C Jacobs director, officer: President and CEO 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Richard J Rodgers director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
James F Young director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Herrmann John A Iii officer: SVP, General Counsel C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Stanley C Erck director, officer: President and CEO 20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
John Trizzino officer: SVP, CBO and CFO 9920 BELWARD CAMPUS DRIVE, ROCKVILLE MD 20850
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
James Patrick Kelly officer: EVP, CFO and Treasurer C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gary C Evans director 1048 TEXAN TRAIL, GRAPEVINE TX 76051
Rachel K. King director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Mcmanus Michael A Jr director 241-02 NORTHERN BLVD, DOUGLASTON NY 11362
Margaret G Mcglynn director C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100